Cover Image
Market Research Report
Product code 
1040229

Human Growth Hormone Market by Application, Route of Administration, and Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2030

Published: | Allied Market Research | 212 Pages | Delivery time: 2-3 business days

Price

Back to Top
Human Growth Hormone Market by Application, Route of Administration, and Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2030
Published: September 28, 2021
Allied Market Research
Content info: 212 Pages
Delivery time: 2-3 business days
  • ALL
  • Description
  • Table of Contents
Description

The global human growth hormone market was valued at $3,864.00 million in 2020 and is expected to reach $9,211.63 million by 2030, registering a CAGR of 9.0% from 2021 to 2030. The human growth hormone also known as somatotropin is a peptide hormone secreted by the pituitary gland that regulates cell growth, cell regeneration & repair, reproduction, and metabolism contributing to the overall development of humans. The growth hormone levels in the human body should be optimum for normal growth and can be regulated by factors such as exercise, sleep, stress, and lower glucose levels. Human growth hormones also help in controlling body composition, muscle & bone growth, body fluids, sugar & fat metabolism, and recovery from injury. It also helps to boost muscle strength & performance. Moreover, lower or higher levels of growth hormone may affect the quality of life thereby, increasing the risks of diseases such as high cholesterol levels, growth hormone deficiency, or poor bone density. Lower levels of human growth hormone increase the risk of diseases and results in fat accumulation throughout the body, whereas higher levels of the same may cause gigantism in children and acromegaly, muscle-wasting disease, and short bowel syndrome in adults. The human growth hormone levels decrease with age. This natural slowdown in the production of growth hormones in human body has triggered the interest in using synthetic growth hormone therapies across the world.

There has been a considerate growth in the human growth hormone market in the recent years due to various factors like rise in adaptation of growth hormones for controlling the aging. Growth Hormone treatment is helping in improving the muscle strength body composition, physical function, and bone density. Growth hormones are also helpful in keeping a check over cardio vascular disorders and are used to decrease the levels of cholesterol in the body. Along with this, there has also been a rise in the disorders related to the growth hormones like Prader-Willi Syndrome, small for gestational age (SGA) and Turner Syndrome due to the wide adoption of sedentary lifestyles and increase consumption of alcohol. This surge is anticipated to propel the growth of the market in the near future. Moreover, rise in the disposable income in the developing economies is expected to create lucrative opportunities in the near future.

Rise in awareness regarding the effectiveness of growth hormones, demand for cost efficient growth hormone therapies; increase in prevalence of serious chronic diseases such as chronic kidney disease and growth retardation, and pituitary dysfunctions; and surge in compliance for growth hormone formulations are the major factors that drive the growth of the global human growth hormone market.

However, the unfavorable effects such as muscle pain, joint pain, and fluid retention associated with the use of synthetic growth hormones and high cost involved in the treatments using these growth hormones hinder the growth of the market. Moreover, stringent government approvals are expected to restrain the growth and development of the market in the coming years. On the contrary, rise in disposable income and surge in healthcare expenditure in developing economies is anticipated to create lucrative opportunities for the manufactures of growth hormones in the future.

The human growth hormone market is segmented on the basis of application, route of administration, distribution channel, and region. By application, it is categorized into growth hormone deficiency, Prader-Willi syndrome, Turner syndrome, small for gestational age, and others. By route of administration, it is classified into intravenous, intramuscular, subcutaneous, and oral. By distribution channel, it is divided into hospital pharmacy, retail pharmacy, clinic, and online pharmacy. Region wise, it is analyzed across North America, Asia-Pacific, Europe, and LAMEA.

The prominent players in the market have adopted various strategies for increasing their market share. These include expansion of their geographical presence through collaborations and partnerships and increase in investment in developing long-acting and effective products with lower adverse effects. Major players operating in the hGH market include Novo Nordisk, Merck & Co., Inc., Eli Lilly and Company, Pfizer Inc., Teva Pharmaceutical Industries Ltd, Novartis AG, AnkeBio Co. Ltd, F. Hoffmann-La Roche, Ipsen, and Ferring BV.

KEY BENEFITS FOR STAKEHOLDERS

  • The study presents an in-depth analysis of the global human growth hormone market along with the current trends and future estimations from 2021 to 2030 to elucidate the imminent investment pockets.
  • A comprehensive analysis of the factors that drive and restrict the market growth is provided.
  • Identification of factors instrumental in changing the market scenario, rise in opportunities, and recognition of the key players that can influence this market on a global & regional scale are provided in the report.
  • Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the market.
  • The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.

KEY MARKET SEGMENTS

  • By Application
  • Growth hormone deficiency
  • Prader-Willi syndrome
  • Turner syndrome
  • Small for gestational age (SGA)
  • Others
  • By Route of Administration
  • Oral
  • Intravenous
  • Intramuscular
  • Subcutaneous
  • By Distribution Channel
  • Hospital pharmacy
  • Retail pharmacy
  • Online Pharmacy
  • By Region
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT

  • Novo Nordisk
  • Merck & Co.
  • Eli Lilly & Company
  • Pfizer Inc.
  • Teva Pharmaceutical Industries
  • Novartis AG
  • Anhui Anke Biotechnology (Group) Co., Ltd
  • Roche
  • Ipsen
  • Ferring BV
Table of Contents
Product Code: LI_195557 / A05192

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1.REPORT DESCRIPTION
  • 1.2.KEY MARKET SEGMENTS
  • 1.3.KEY BENEFITS
  • 1.4.RESEARCH METHODOLOGY
    • 1.4.1.Primary research
    • 1.4.2.Secondary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.CXO PERSPECTIVE

CHAPTER 3:MARKET LANDSCAPE

  • 3.1.MARKET DEFINITION AND SCOPE
  • 3.2.KEY FINDINGS
    • 3.2.1.Top investment pockets
    • 3.2.2.Top winning strategies
  • 3.3.PORTER'S FIVE FORCES ANALYSIS
    • 3.3.1.Bargaining power of suppliers
    • 3.3.2.Threat of new entrants
    • 3.3.3.Threat of substitutes
    • 3.3.4.Competitive rivalry
    • 3.3.5.Bargaining power among buyers
  • 3.4.MARKET SHARE ANALYSIS/TOP PLAYER POSITIONING
  • 3.5.MARKET DYNAMICS
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities

CHAPTER 4:HUMAN GROWTH HORMONE MARKET, BY APPLICATION

  • 4.1.OVERVIEW
  • 4.2.GROWTH HORMONE DEFICIENCY
    • 4.2.1.Key market trends, Growth factors and opportunities
    • 4.2.2.Market size and forecast by region
    • 4.2.3.Market analysis by country
  • 4.3.PRADER-WILLI SYNDROME
    • 4.3.1.Key market trends, Growth factors and opportunities
    • 4.3.2.Market size and forecast by region
    • 4.3.3.Market analysis by country
  • 4.4.TURNER SYNDROME
    • 4.4.1.Key market trends, Growth factors and opportunities
    • 4.4.2.Market size and forecast by region
    • 4.4.3.Market analysis by country
  • 4.5.SMALL FOR GESTATIONAL AGE (SGA)
    • 4.5.1.Key market trends, Growth factors and opportunities
    • 4.5.2.Market size and forecast by region
    • 4.5.3.Market analysis by country
  • 4.6.OTHERS
    • 4.6.1.Key market trends, Growth factors and opportunities
    • 4.6.2.Market size and forecast by region
    • 4.6.3.Market analysis by country

CHAPTER 5:HUMAN GROWTH HORMONE MARKET, BY ROUTE OF ADMINISTRATION

  • 5.1.OVERVIEW
  • 5.2.ORAL
    • 5.2.1.Key market trends, Growth factors and opportunities
    • 5.2.2.Market size and forecast by region
    • 5.2.3.Market analysis by country
  • 5.3.INTRAVENOUS
    • 5.3.1.Key market trends, Growth factors and opportunities
    • 5.3.2.Market size and forecast by region
    • 5.3.3.Market analysis by country
  • 5.4.INTRAMUSCULAR
    • 5.4.1.Key market trends, Growth factors and opportunities
    • 5.4.2.Market size and forecast by region
    • 5.4.3.Market analysis by country
  • 5.5.SUBCUTANEOUS
    • 5.5.1.Key market trends, Growth factors and opportunities
    • 5.5.2.Market size and forecast by region
    • 5.5.3.Market analysis by country

CHAPTER 6:HUMAN GROWTH HORMONE MARKET, BY DISTRIBUTION CHANNEL

  • 6.1.OVERVIEW
  • 6.2.HOSPITAL PHARMACY
    • 6.2.1.Key market trends, Growth factors and opportunities
    • 6.2.2.Market size and forecast by region
    • 6.2.3.Market analysis by country
  • 6.3.RETAIL PHARMACY
    • 6.3.1.Key market trends, Growth factors and opportunities
    • 6.3.2.Market size and forecast by region
    • 6.3.3.Market analysis by country
  • 6.4.ONLINE PHARMACY
    • 6.4.1.Key market trends, Growth factors and opportunities
    • 6.4.2.Market size and forecast by region
    • 6.4.3.Market analysis by country

CHAPTER 7:HUMAN GROWTH HORMONE MARKET, BY REGION

  • 7.1.OVERVIEW
  • 7.2.NORTH AMERICA
    • 7.2.1.Key market trends and opportunities
    • 7.2.2.Market size and forecast by Application
    • 7.2.3.Market size and forecast by Route of Administration
    • 7.2.4.Market size and forecast by Distribution Channel
    • 7.2.5.Market size and forecast by Country
    • 7.2.6.US HUMAN GROWTH HORMONE MARKET
      • 7.2.6.1.Market size and forecast by Application
      • 7.2.6.2.Market size and forecast by Route of Administration
      • 7.2.6.3.Market size and forecast by Distribution Channel
    • 7.2.7.CANADA HUMAN GROWTH HORMONE MARKET
      • 7.2.7.1.Market size and forecast by Application
      • 7.2.7.2.Market size and forecast by Route of Administration
      • 7.2.7.3.Market size and forecast by Distribution Channel
    • 7.2.8.MEXICO HUMAN GROWTH HORMONE MARKET
      • 7.2.8.1.Market size and forecast by Application
      • 7.2.8.2.Market size and forecast by Route of Administration
      • 7.2.8.3.Market size and forecast by Distribution Channel
  • 7.3.EUROPE
    • 7.3.1.Key market trends and opportunities
    • 7.3.2.Market size and forecast by Application
    • 7.3.3.Market size and forecast by Route of Administration
    • 7.3.4.Market size and forecast by Distribution Channel
    • 7.3.5.Market size and forecast by Country
    • 7.3.6.FRANCE HUMAN GROWTH HORMONE MARKET
      • 7.3.6.1.Market size and forecast by Application
      • 7.3.6.2.Market size and forecast by Route of Administration
      • 7.3.6.3.Market size and forecast by Distribution Channel
    • 7.3.7.UK HUMAN GROWTH HORMONE MARKET
      • 7.3.7.1.Market size and forecast by Application
      • 7.3.7.2.Market size and forecast by Route of Administration
      • 7.3.7.3.Market size and forecast by Distribution Channel
    • 7.3.8.GERMANY HUMAN GROWTH HORMONE MARKET
      • 7.3.8.1.Market size and forecast by Application
      • 7.3.8.2.Market size and forecast by Route of Administration
      • 7.3.8.3.Market size and forecast by Distribution Channel
    • 7.3.9.SPAIN HUMAN GROWTH HORMONE MARKET
      • 7.3.9.1.Market size and forecast by Application
      • 7.3.9.2.Market size and forecast by Route of Administration
      • 7.3.9.3.Market size and forecast by Distribution Channel
    • 7.3.10.REST OF EUROPE HUMAN GROWTH HORMONE MARKET
      • 7.3.10.1.Market size and forecast by Application
      • 7.3.10.2.Market size and forecast by Route of Administration
      • 7.3.10.3.Market size and forecast by Distribution Channel
  • 7.4.ASIA-PACIFIC
    • 7.4.1.Key market trends and opportunities
    • 7.4.2.Market size and forecast by Application
    • 7.4.3.Market size and forecast by Route of Administration
    • 7.4.4.Market size and forecast by Distribution Channel
    • 7.4.5.Market size and forecast by Country
    • 7.4.6.JAPAN HUMAN GROWTH HORMONE MARKET
      • 7.4.6.1.Market size and forecast by Application
      • 7.4.6.2.Market size and forecast by Route of Administration
      • 7.4.6.3.Market size and forecast by Distribution Channel
    • 7.4.7.CHINA HUMAN GROWTH HORMONE MARKET
      • 7.4.7.1.Market size and forecast by Application
      • 7.4.7.2.Market size and forecast by Route of Administration
      • 7.4.7.3.Market size and forecast by Distribution Channel
    • 7.4.8.INDIA HUMAN GROWTH HORMONE MARKET
      • 7.4.8.1.Market size and forecast by Application
      • 7.4.8.2.Market size and forecast by Route of Administration
      • 7.4.8.3.Market size and forecast by Distribution Channel
    • 7.4.9.AUSTRALIA HUMAN GROWTH HORMONE MARKET
      • 7.4.9.1.Market size and forecast by Application
      • 7.4.9.2.Market size and forecast by Route of Administration
      • 7.4.9.3.Market size and forecast by Distribution Channel
    • 7.4.10.REST OF ASIA-PACIFIC HUMAN GROWTH HORMONE MARKET
      • 7.4.10.1.Market size and forecast by Application
      • 7.4.10.2.Market size and forecast by Route of Administration
      • 7.4.10.3.Market size and forecast by Distribution Channel
  • 7.5.LAMEA
    • 7.5.1.Key market trends and opportunities
    • 7.5.2.Market size and forecast by Application
    • 7.5.3.Market size and forecast by Route of Administration
    • 7.5.4.Market size and forecast by Distribution Channel
    • 7.5.5.Market size and forecast by Country
    • 7.5.6.BRAZIL HUMAN GROWTH HORMONE MARKET
      • 7.5.6.1.Market size and forecast by Application
      • 7.5.6.2.Market size and forecast by Route of Administration
      • 7.5.6.3.Market size and forecast by Distribution Channel
    • 7.5.7.SAUDI ARABIA HUMAN GROWTH HORMONE MARKET
      • 7.5.7.1.Market size and forecast by Application
      • 7.5.7.2.Market size and forecast by Route of Administration
      • 7.5.7.3.Market size and forecast by Distribution Channel
    • 7.5.8.SOUTH AFRICA HUMAN GROWTH HORMONE MARKET
      • 7.5.8.1.Market size and forecast by Application
      • 7.5.8.2.Market size and forecast by Route of Administration
      • 7.5.8.3.Market size and forecast by Distribution Channel
    • 7.5.9.REST OF LAMEA HUMAN GROWTH HORMONE MARKET
      • 7.5.9.1.Market size and forecast by Application
      • 7.5.9.2.Market size and forecast by Route of Administration
      • 7.5.9.3.Market size and forecast by Distribution Channel

CHAPTER 8: COMPANY PROFILES

  • 8.1.NOVO NORDISK
    • 8.1.1.Company overview
    • 8.1.2.Key Executives
    • 8.1.3.Company snapshot
    • 8.1.4.Operating business segments
    • 8.1.5.Product portfolio
    • 8.1.6.Business performance
    • 8.1.7.Key strategic moves and developments
  • 8.2.MERCK & CO.
    • 8.2.1.Company overview
    • 8.2.2.Key Executives
    • 8.2.3.Company snapshot
    • 8.2.4.Operating business segments
    • 8.2.5.Product portfolio
    • 8.2.6.Business performance
    • 8.2.7.Key strategic moves and developments
  • 8.3.ELI LILLY AND COMPANY
    • 8.3.1.Company overview
    • 8.3.2.Key Executives
    • 8.3.3.Company snapshot
    • 8.3.4.Operating business segments
    • 8.3.5.Product portfolio
    • 8.3.6.Business performance
    • 8.3.7.Key strategic moves and developments
  • 8.4.PFIZER INC.
    • 8.4.1.Company overview
    • 8.4.2.Key Executives
    • 8.4.3.Company snapshot
    • 8.4.4.Operating business segments
    • 8.4.5.Product portfolio
    • 8.4.6.Business performance
    • 8.4.7.Key strategic moves and developments
  • 8.5.TEVA PHARMACEUTICAL INDUSTRIES
    • 8.5.1.Company overview
    • 8.5.2.Key Executives
    • 8.5.3.Company snapshot
    • 8.5.4.Operating business segments
    • 8.5.5.Product portfolio
    • 8.5.6.Business performance
    • 8.5.7.Key strategic moves and developments
  • 8.6.NOVARTIS AG
    • 8.6.1.Company overview
    • 8.6.2.Key Executives
    • 8.6.3.Company snapshot
    • 8.6.4.Operating business segments
    • 8.6.5.Product portfolio
    • 8.6.6.Business performance
    • 8.6.7.Key strategic moves and developments
  • 8.7.ANHUI ANKE BIOTECHNOLOGY (GROUP) CO. LTD.
    • 8.7.1.Company overview
    • 8.7.2.Key Executives
    • 8.7.3.Company snapshot
    • 8.7.4.Operating business segments
    • 8.7.5.Product portfolio
    • 8.7.6.Business performance
    • 8.7.7.Key strategic moves and developments
  • 8.8.ROCHE
    • 8.8.1.Company overview
    • 8.8.2.Key Executives
    • 8.8.3.Company snapshot
    • 8.8.4.Operating business segments
    • 8.8.5.Product portfolio
    • 8.8.6.Business performance
    • 8.8.7.Key strategic moves and developments
  • 8.9.IPSEN
    • 8.9.1.Company overview
    • 8.9.2.Key Executives
    • 8.9.3.Company snapshot
    • 8.9.4.Operating business segments
    • 8.9.5.Product portfolio
    • 8.9.6.Business performance
    • 8.9.7.Key strategic moves and developments
  • 8.10.FERRING BV
    • 8.10.1.Company overview
    • 8.10.2.Key Executives
    • 8.10.3.Company snapshot
    • 8.10.4.Operating business segments
    • 8.10.5.Product portfolio
    • 8.10.6.Business performance
    • 8.10.7.Key strategic moves and developments

LIST OF TABLES

  • TABLE 01.GLOBAL HUMAN GROWTH HORMONE MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 02.GROWTH HORMONE DEFICIENCY MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 03.PRADER-WILLI SYNDROME MARKET BY REGION 2020-2030 ($MILLION)
  • TABLE 04.TURNER SYNDROME MARKET BY REGION 2020-2030 ($MILLION)
  • TABLE 05.HUMAN GROWTH HORMONE MARKET FOR SMALL FOR GESTATIONAL AGE (SGA) MARKET BY REGION, 2020-2030 ($MILLION)
  • TABLE 06.HUMAN GROWTH HORMONE MARKET FOR OTHER APPLICATIONS BY REGION 2020-2030 ($MILLION)
  • TABLE 07.GLOBAL HUMAN GROWTH HORMONE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 08.ORAL ROUTE OF ADMINSTRATION BY REGION, 2020-2030 ($MILLION)
  • TABLE 09.INTRAVENOUS ROUTE OF ADMINISTRATION MARKET BY REGION 2020-2030 ($MILLION)
  • TABLE 10.INTRAMUSCULAR ROUTE OF ADMINISTRATION MARKET BY REGION 2020-2030 ($MILLION)
  • TABLE 11.SUBCUTANEOUS ROUTE OF ADMINISTRATION MARKET BY REGION 2020-2030 ($MILLION)
  • TABLE 12.GLOBAL HUMAN GROWTH HORMONE MARKET, DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 13.HOSPITAL PHARMACY HUMAN GROWTH HORMONE MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 14.RETAIL PHARMACY HUMAN GROWTH HORMONE MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 15.ONLINE PHARMACY HUMAN GROWTH HORMONE MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 16.HUMAN GROWTH HORMONE MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 17.NORTH AMERICA HUMAN GROWTH HORMONE MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 18.NORTH AMERICA HUMAN GROWTH HORMONE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 19.NORTH AMERICA HUMAN GROWTH HORMONE MARKET, DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 20.U.S. HUMAN GROWTH HORMONE MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 21.U.S. HUMAN GROWTH HORMONE MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 22.U.S. HUMAN GROWTH HORMONE MARKET, DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 23.CANADA HUMAN GROWTH HORMONE MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 24.CANADA HUMAN GROWTH HORMONE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 25.CANADA HUMAN GROWTH HORMONE MARKET, DISTRIBUTION CHANNEL, 2020-2030($MILLION)
  • TABLE 26.MEXICO HUMAN GROWTH HORMONE MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 27.MEXICO HUMAN GROWTH HORMONE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 28.MEXICO HUMAN GROWTH HORMONE MARKET, DISTRIBUTION CHANNEL, 2020-2030($MILLION)
  • TABLE 29.EUROPE HUMAN GROWTH HORMONE MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 30.EUROPE HUMAN GROWTH HORMONE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 31.EUROPE HUMAN GROWTH HORMONE MARKET, DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 32.EUROPE HUMAN GROWTH HORMONE MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 33.FRANCE HUMAN GROWTH HORMONE MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 34.FRANCE HUMAN GROWTH HORMONE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 35.FRANCE HUMAN GROWTH HORMONE MARKET, DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 36.UK HUMAN GROWTH HORMONE MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 37.UK HUMAN GROWTH HORMONE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 38.UK HUMAN GROWTH HORMONE MARKET, DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 39.GERMANY HUMAN GROWTH HORMONE MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 40.GERMANY HUMAN GROWTH HORMONE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 41.GERMANY HUMAN GROWTH HORMONE MARKET, DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 42.SPAIN HUMAN GROWTH HORMONE MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 43.SPAIN HUMAN GROWTH HORMONE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 44.SPAIN HUMAN GROWTH HORMONE MARKET, DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 45.REST OF EUROPE HUMAN GROWTH HORMONE MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 46.REST OF EUROPE HUMAN GROWTH HORMONE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 47.REST OF EUROPE HUMAN GROWTH HORMONE MARKET, DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 48.ASIA-PACIFIC HUMAN GROWTH HORMONE MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 49.ASIA-PACIFIC HUMAN GROWTH HORMONE MARKET, BY ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 50.ASIA-PACIFIC HUMAN GROWTH HORMONE MARKET, DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 51.ASIA-PACIFIC HUMAN GROWTH HORMONE MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 52.JAPAN HUMAN GROWTH HORMONE MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 53.JAPAN HUMAN GROWTH HORMONE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 54.JAPAN HUMAN GROWTH HORMONE MARKET, DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 55.CHINA HUMAN GROWTH HORMONE MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 56.CHINA HUMAN GROWTH HORMONE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 57.CHINA HUMAN GROWTH HORMONE MARKET, DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 58.INDIA HUMAN GROWTH HORMONE MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 59.INDIA HUMAN GROWTH HORMONE MARKET, BY ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 60.INDIA HUMAN GROWTH HORMONE MARKET, DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 61.AUSTRALIA HUMAN GROWTH HORMONE MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 62.AUSTRALIA HUMAN GROWTH HORMONE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 63.AUSTRALIA HUMAN GROWTH HORMONE MARKET, DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 64.REST OF ASIA-PACIFIC HUMAN GROWTH HORMONE MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 65.REST OF ASIA-PACIFIC HUMAN GROWTH HORMONE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 66.REST OF ASIA-PACIFIC HUMAN GROWTH HORMONE MARKET, DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 67.LAMEA HUMAN GROWTH HORMONE MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 68.LAMEA HUMAN GROWTH HORMONE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 69.LAMEA HUMAN GROWTH HORMONE MARKET, DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 70.LAMEA HUMAN GROWTH HORMONE MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 71.BRAZIL HUMAN GROWTH HORMONE MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 72.BRAZIL HUMAN GROWTH HORMONE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 73.BRAZIL HUMAN GROWTH HORMONE MARKET, DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 74.SAUDI ARABIA HUMAN GROWTH HORMONE MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 75.SAUDI ARABIA HUMAN GROWTH HORMONE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 76.SAUDI ARABIA HUMAN GROWTH HORMONE MARKET, DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 77.SOUTH AFRICA HUMAN GROWTH HORMONE MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 78.SOUTH AFRICA HUMAN GROWTH HORMONE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 79.SOUTH AFRICA HUMAN GROWTH HORMONE MARKET, DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 80.REST OF LAMEA HUMAN GROWTH HORMONE MARKET, BY APPLICATION, 2020-2030 ($MILLION)
  • TABLE 81.REST OF LAMEA HUMAN GROWTH HORMONE MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 ($MILLION)
  • TABLE 82.REST OF LAMEA HUMAN GROWTH HORMONE MARKET, DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 83.NOVO NORDISK: COMPANY SNAPSHOT
  • TABLE 84.NOVO NORDISK: OPERATING SEGMENTS
  • TABLE 85.NOVO NORDISK PLC: PRODUCT PORTFOLIO
  • TABLE 86.MERCK & CO.: COMPANY SNAPSHOT
  • TABLE 87.MERCK & CO. INC.: OPERATING SEGMENTS
  • TABLE 88.MERCK & CO. INC.: PRODUCT PORTFOLIO
  • TABLE 89.ELI LILLY AND COMPANY.: COMPANY SNAPSHOT
  • TABLE 90.ELI LILLY AND COMPANY.: OPERATING SEGMENTS
  • TABLE 91.ELI LILLY AND COMPANY.: PRODUCT PORTFOLIO:
  • TABLE 92.PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 93.PFIZER INC.: OPERATING SEGMENTS
  • TABLE 94.PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 95.TEVA PHARMACEUTICAL INDUSTRIES.: COMPANY SNAPSHOT
  • TABLE 96.TEVA PHARMACEUTICAL INDUSTRIES.: OPERATING SEGMENTS
  • TABLE 97.TEVA PHARMACEUTICAL INDUSTRIES.: PRODUCT PORTFOLIO
  • TABLE 98.NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 99.NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 100.NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 101.ANHUI ANKE BIOTECHNOLOGY (GROUP) CO., LTD.: COMPANY SNAPSHOT
  • TABLE 102.ANHUI ANKE BIOTECHNOLOGY (GROUP) CO., LTD.: OPERATING SEGMENTS
  • TABLE 103.ANHUI ANKE BIOTECHNOLOGY (GROUP) CO., LTD: PRODUCT PORTFOLIO
  • TABLE 104.ROCHE: COMPANY SNAPSHOT
  • TABLE 105.ROCHE: OPERATING SEGMENTS
  • TABLE 106.ROCHE: PRODUCT PORTFOLIO
  • TABLE 107.IPSEN: COMPANY SNAPSHOT
  • TABLE 108.IPSEN: PRODUCT SEGMENTS
  • TABLE 109.IPSEN: PRODUCT PORTFOLIO
  • TABLE 110.FERRING BV.: COMPANY SNAPSHOT
  • TABLE 111.FERRING BV.: OPERATING SEGMENTS
  • TABLE 112.FERRING BV: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.GLOBAL HUMAN GROWTH HORMONE MARKET SEGMENTATION
  • FIGURE 02.LOW-TO- MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 03.MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 04.MODERATE THREAT OF SUBSTITUTES
  • FIGURE 05.LOW-TO-MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 06.LOW COMPETITIVE RIVALARY
  • FIGURE 07.TOP PLAYER POSITIONING, 2020
  • FIGURE 08.TOP INVESTMENT POCKETS
  • FIGURE 09.DRIVERS AND RESTRAINTS
  • FIGURE 10.COMPARATIVE SHARE ANALYSIS OF HUMAN GROWTH HORMONE MARKET FOR GROWTH HORMONE DEFICIENCY, BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 11.COMPARATIVE SHARE ANALYSIS OF HUMAN GROWTH HORMONE MARKET FOR PRADER WILLI, BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 12.COMPARATIVE SHARE ANALYSIS OF HUMAN GROWTH HORMONE MARKET FOR TURNER SYNDROME, BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF HUMAN GROWTH HORMONE MARKET FOR SGH, BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF HUMAN GROWTH HORMONE MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF HUMAN GROWTH HORMONE MARKET FOR ORAL, BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF HUMAN GROWTH HORMONE MARKET FOR INTRAVENOUS, BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF HUMAN GROWTH HORMONE MARKET FOR INTRAMUSCULAR, BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF HUMAN GROWTH HORMONE MARKET FOR SUBCUTANEOUS, BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF HUMAN GROWTH HORMONE MARKET, FOR HOSPITALS, BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF HUMAN GROWTH HORMONE MARKET FOR RETAIL PHARMACY, BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 21.COMPARATIVE SHARE ANALYSIS OF HUMAN GROWTH HORMONE MARKET FOR ONLINE PHARMACY, BY COUNTRY, 2020 & 2030(%)
  • FIGURE 22.NOVO NORDISK: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 23.NOVO NORDISK: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 24.MERCK & CO.: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 25.MERCK & CO.: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 26.MERCK & CO.: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 27.ELI LILLY AND COMPANY: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 28.ELI LILLY AND COMPANY: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 29.ELI LILLY AND COMPANY: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 30.PFIZER: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 31.PFIZER. REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 32.PFIZER INC: REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 33.TEVA PHARMACEUTICAL INDUSTRIES.: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 34.TEVA PHARMACEUTICAL INDUSTRIES. REVENUE SHARE BY REGIONS, 2020 (%)
  • FIGURE 35.NOVARTIS AG: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 36.NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 37.ROCHE: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 38.ROCHE: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 39.ROCHE: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 40.IPSEN: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 41.IPSEN: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 42.IPSEN: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 43.FERRING BV.: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 44.FERRING BV. REVENUE SHARE BY REGION, 2020(%)
  • FIGURE 45.FERRING BV: REVENUE SHARE BY SEGMENT, 2020 (%)